SEARCH:   Advanced

Blood, 1 February 2006, Vol. 107, No. 3, pp. 885-891. Prepublished online as a Blood First Edition Paper on October 11, 2005; DOI 10.1182/blood-2005-06-2395. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-06-2395v1 107/3/885    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Eichhorst, B. F. Articles by Hallek, M. Search for Related Content PubMed PubMed Citation Articles by Eichhorst, B. F. Articles by Hallek, M. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Barbara F. Eichhorst, Raymonde Busch, Georg Hopfinger, Rita Pasold, Manfred Hensel, Cordelia Steinbrecher, Siegfried Siehl, Ulrich Jäger, Manuela Bergmann, Stephan Stilgenbauer, Carmen Schweighofer, Clemens M. Wendtner, Hartmut Döhner, Günter Brittinger, Bertold Emmerich, Michael Hallek, the German CLL Study Group From the Department of Internal Medicine I, University of Cologne, Cologne, Germany; Institute of Medical Statistics and Epidemiology, Technical University, Munich, Germany; Hanusch Hospital, Vienna, Austria; Ernst-von-Bergmann Hospital, Potsdam, Germany; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; Hospital Barmherzige Brüder, Regensburg, Germany; Internistische Gemeinschaftspraxis Prof Hirschmann/Dr Siehl/Dr Soling, Clinic for Internal Medicine, Kassel, Germany; Medical University of Vienna, Department of Internal Medicine I, Vienna, Austria; Department of Internal Medicine III, Ludwig-Maximilians-University of Munich, Munich, Germany; Department of Internal Medicine III, University of Ulm, Ulm, Germany; Department of Hematology, University of Duisburg-Essen, Essen, Germany; and Department of Internal Medicine Innenstadt, Ludwig-Maximilians-University of Munich, Munich, Germany. Combination chemotherapy with fludarabine plus cyclophosphamide (FC) was compared with the standard regimen of fludarabine monotherapy in first-line treatment of younger patients with chronic lymphocytic leukemia (CLL). Between 1999 and 2003, a total of 375 patients younger than 66 years who predominantly had advanced CLL were randomly assigned to receive either fludarabine (25 mg/m2 for 5 days intravenously, repeated every 28 days) or FC combination therapy (fludarabine 30 mg/m2 plus cyclophosphamide 250 mg/m2 for 3 days intravenously, repeated every 28 days). Both regimens were administered to a maximum of 6 courses. FC combination chemotherapy resulted in significantly higher complete remission rate (24%) and overall response rate (94%) compared with fludarabine alone (7% and 83%; P < .001 and P = .001). FC treatment also resulted in longer median progression-free survival (48 vs 20 months; P = .001) and longer treatment-free survival (37 vs 25 months; P < .001). Thus far, no difference in median overall survival has been observed. FC caused significantly more thrombocytopenia and leukocytopenia but did not increase the number of severe infections. In summary, first-line treatment with FC increases the response rates and the treatment-free interval in younger patients with advanced CLL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Treatment and evaluation of CLL: a complicated affair Neil E. Kay Blood 2006 107: 848. [Full Text] [PDF] This article has been cited by other articles: G. G. Johnson, P. D. Sherrington, A. Carter, K. Lin, T. Liloglou, J. K. Field, and A. R. Pettitt A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene Cancer Res., June 15, 2009; 69(12): 5210 - 5217. [Abstract] [Full Text] [PDF] C.-Y. Tsai, A. S. Ray, D. B. Tumas, M. J. Keating, H. Reiser, and W. Plunkett Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219 Clin. Cancer Res., June 1, 2009; 15(11): 3760 - 3769. [Abstract] [Full Text] [PDF] B. Eichhorst, M. Hallek, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Chronic lymphocytic leukemia: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv102 - iv104. [Full Text] [PDF] N. Lamanna, J. G. Jurcic, A. Noy, P. Maslak, A. N. Gencarelli, K. S. Panageas, M. L. Heaney, R. J. Brentjens, D. W. Golde, D. A. Scheinberg, et al. Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses J. Clin. Oncol., February 1, 2009; 27(4): 491 - 497. [Abstract] [Full Text] [PDF] K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al. Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., February 1, 2009; 27(4): 498 - 503. [Abstract] [Full Text] [PDF] J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER Chronic Lymphocytic Leukaemia Anticancer Res, February 1, 2009; 29(2): 605 - 615. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF] P. Hillmen In Reply J. Clin. Oncol., December 10, 2008; 26(35): 5828 - 5829. [Full Text] [PDF] C. Nabhan Frontline Therapy for Chronic Lymphocytic Leukemia: The Dilemma Continues Clin. Cancer Res., July 1, 2008; 14(13): 4353 - 4353. [Full Text] [PDF] V. Gandhi, C. Tam, S. O'Brien, R. C. Jewell, C. O. Rodriguez Jr, S. Lerner, W. Plunkett, and M. J. Keating Phase I Trial of Nelarabine in Indolent Leukemias J. Clin. Oncol., March 1, 2008; 26(7): 1098 - 1105. [Abstract] [Full Text] [PDF] C. Dearden, R. Wade, M. Else, S. Richards, D. Milligan, T. Hamblin, D. Catovsky, and for the UK National Cancer Research Institute (NCR The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia Blood, February 15, 2008; 111(4): 1820 - 1826. [Abstract] [Full Text] [PDF] E. Gine, M. Crespo, A. Muntanola, E. Calpe, M. J. Baptista, N. Villamor, E. Montserrat, and F. Bosch Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment Haematologica, January 1, 2008; 93(1): 75 - 82. [Abstract] [Full Text] [PDF] F. Bosch, A. Ferrer, N. Villamor, M. Gonzalez, J. Briones, E. Gonzalez-Barca, E. Abella, S. Gardella, L. Escoda, E. Perez-Ceballos, et al. Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication Clin. Cancer Res., January 1, 2008; 14(1): 155 - 161. [Abstract] [Full Text] [PDF] W. G. Wierda Treatments for Patients with Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305. [Abstract] [Full Text] [PDF] K. A. Blum, D. Young, S. Broering, M. S. Lucas, B. Fischer, T. S. Lin, M. R. Grever, and J. C. Byrd Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria J. Clin. Oncol., December 10, 2007; 25(35): 5624 - 5629. [Abstract] [Full Text] [PDF] P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia J. Clin. Oncol., December 10, 2007; 25(35): 5616 - 5623. [Abstract] [Full Text] [PDF] J. M. Flynn and J. C. Byrd Have We Forgotten the Purpose of Phase III Studies? J. Clin. Oncol., December 10, 2007; 25(35): 5553 - 5555. [Full Text] [PDF] A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF] J. E. Karp, R. M. Ricklis, K. Balakrishnan, J. Briel, J. Greer, S. D. Gore, B. D. Smith, M. A. McDevitt, H. Carraway, M. J. Levis, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias Blood, September 15, 2007; 110(6): 1762 - 1769. [Abstract] [Full Text] [PDF] J. C. Byrd, S. O'Brien, I. W. Flinn, T. J. Kipps, M. Weiss, K. Rai, T. S. Lin, J. Woodworth, D. Wynne, J. Reid, et al. Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Clin. Cancer Res., August 1, 2007; 13(15): 4448 - 4455. [Abstract] [Full Text] [PDF] J. G. Gribben How I treat indolent lymphoma Blood, June 1, 2007; 109(11): 4617 - 4626. [Abstract] [Full Text] [PDF] B. F. Eichhorst, R. Busch, T. Obwandner, I. Kuhn-Hallek, P. Herschbach, and M. Hallek Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group J. Clin. Oncol., May 1, 2007; 25(13): 1722 - 1731. [Abstract] [Full Text] [PDF] S. O'Brien, J. O. Moore, T. E. Boyd, L. M. Larratt, A. Skotnicki, B. Koziner, A. A. Chanan-Khan, J. F. Seymour, R. G. Bociek, S. Pavletic, et al. Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia J. Clin. Oncol., March 20, 2007; 25(9): 1114 - 1120. [Abstract] [Full Text] [PDF] I. W. Flinn, D. S. Neuberg, M. R. Grever, G. W. Dewald, J. M. Bennett, E. M. Paietta, M. A. Hussein, F. R. Appelbaum, R. A. Larson, D. F. Moore Jr, et al. Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 J. Clin. Oncol., March 1, 2007; 25(7): 793 - 798. [Abstract] [Full Text] [PDF] M. R. Grever, D. M. Lucas, G. W. Dewald, D. S. Neuberg, J. C. Reed, S. Kitada, I. W. Flinn, M. S. Tallman, F. R. Appelbaum, R. A. Larson, et al. Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 J. Clin. Oncol., March 1, 2007; 25(7): 799 - 804. [Abstract] [Full Text] [PDF] N. E. Kay, S. M. Geyer, T. G. Call, T. D. Shanafelt, C. S. Zent, D. F. Jelinek, R. Tschumper, N. D. Bone, G. W. Dewald, T. S. Lin, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Blood, January 15, 2007; 109(2): 405 - 411. [Abstract] [Full Text] [PDF] T. D. Shanafelt and N. E. Kay Comprehensive Management of the CLL Patient: A Holistic Approach Hematology, January 1, 2007; 2007(1): 324 - 331. [Abstract] [Full Text] [PDF] V. A. Morrison Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia Hematology, January 1, 2007; 2007(1): 332 - 338. [Abstract] [Full Text] [PDF] T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med, September 19, 2006; 145(6): 435 - 447. [Abstract] [Full Text] [PDF] F. Naumann, O. Weingart, E. Kruse, H. Schulz, J. Bohlius, H. Hulsewede, and A. Engert Fifth biannual report of the cochrane haematologic malignancies group--focus on multiple myeloma. J Natl Cancer Inst, August 16, 2006; 98(16): E2 - EE. [Full Text] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] T. Robak, J. Z. Blonski, J. Gora-Tybor, K. Jamroziak, J. Dwilewicz-Trojaczek, A. Tomaszewska, L. Konopka, B. Ceglarek, A. Dmoszynska, M. Kowal, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) Blood, July 15, 2006; 108(2): 473 - 479. [Abstract] [Full Text] [PDF] N. Lamanna, M. Kalaycio, P. Maslak, J. G. Jurcic, M. Heaney, R. Brentjens, A. D. Zelenetz, D. Horgan, A. Gencarelli, K. S. Panageas, et al. Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia J. Clin. Oncol., April 1, 2006; 24(10): 1575 - 1581. [Abstract] [Full Text] [PDF] W. G. Wierda Current and Investigational Therapies for Patients with CLL Hematology, January 1, 2006; 2006(1): 285 - 294. [Abstract] [Full Text] [PDF] I. F. Khouri Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Hematology, January 1, 2006; 2006(1): 390 - 397. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020